



国家卫生计生委卫生发展研究中心
China National Health Development Research Center

China HTA Development

Prof Kun Zhao
Division Director of HTA
China National Health Development Research Center
(CNHDRC)
September , 2018
Ghana



Institutional--Challenges and Opportunities

Challenges:

- HTA Legislation
 - Conflict of Interest
- HTA Mechanism
 - Multi-sectors/
Interdisciplinary
 - HTA Norm and
Regulation
 - HTA Course

Opportunities:

- Central Government Commitment and Progress been Made
 - Government Document
- Mapping HTA Mechanism in China
 - HTA Mechanism (National HTA Center Located at CNHDRC)
 - HTA Guideline and Manual
 - Capacity Building



HTA Institutional Building in China 2016-18

- ▶ *<Guidance on Strengthening the Technology>* issued at Oct, 2016 translation and transformation
- ▶ *<Guidance on Strengthening HTA>*
- ▶ *<Basic Health Law >* (Drafting, n
- ▶ *<Guidance on Comprehensive Su* August, 2018 –Document No.63 , technology management)
- ▶ **The Key Tasks in NHC in 2018 :** technologies such as The list, HCV
- ▶ **National HTA Center:** The Center Conference

科技教育司

网站导航: 站首页 | 首页 | 最新信息 | 政策文件 | 工作动态 | 关于我们 | 图片集锦 | 专题专栏

公文

您现在的位置: 首页 > 最新信息 > 重大专项 > 公文

关于加强卫生与健康科技成果转移转化工作的指导意见

发布时间: 2016-10-12

国卫科教发〔2016〕51号

各省、自治区、直辖市卫生计生委、科技厅(委、局)、食品药品监管局、中医药管理局, 新疆生产建设兵团卫生局、人口计生委、科技局、食品药品监管局, 军队有关卫生部门:

为深入贯彻落实创新驱动发展战略, 促进卫生与健康科技成果转移转化与推广应用, 依据《中

(四) 加强卫生技术评估与科技成果评价工作。
 建设卫生技术评估体系。制定卫生技术评估指导意见, 建立若干国家级卫生技术评估中心, 加强卫生技术评估机构和队伍建设, 发展循证医学, 构建适应医疗、卫生、科研等各类机构需求和卫生与健康产品、高新与适宜技术等不同科技成果类型的评估方法, 促进卫生技术评估结果的传播和政策转化。
 建立健全科技成果评价制度。建设卫生技术评估和科技成果评价专家库, 积极推行科技成果第三方评价, 构建政府、专业机构、学术团体、企业和公众等多方参与的评价机制, 提高评价的科学

(九) 优化医疗卫生服务要素准入。加快推进医药卫生领域行政审批制度改革, 相关部门按职责建立行政审批事项清单并向社会公示。优化医疗卫生机构、从业人员以及医疗技术、药品、医疗器械等准入和行政许可流程, 推行医疗机构、医师和护士电子化注册。制定社会办医疗机构设置的跨部门全流程综合审批办法。强化国家卫生技术评估支持力量, 发挥卫生技术评估在医疗技术、药品、医疗器械等临床准入、规范应用、停用、淘汰等方面的决策支持作用。



HTA Action Taken By National Government 2018


Industry Provided HTA Dossiers:

- Pricing Negotiation For 18 Generic Cancer Drugs
- Pricing Negotiation For High Cost Drugs And Consumable Medical Materials

HTA Conducted When Evidence Absent or Insufficient :

- Updating National Essential Drug List
- Reviewing Public Health Service Package (with 41 Interventions, Funded by MoF 60 Billion/Year RMB)(just initiate)
- Setting Up the List of Appropriate Technologies in County Level Hospitals

Mapping of HTA Work in China






国家卫生计生委卫生发展研究中心
China National Health Development Research Center

Political Commitment on Health Policy And Technology Assessment Network



Health Minister Xiaowei Ma and Deputy Health Minister Yixin Zeng

HTA Projects Commissioned by MoH and Other Organizations in 2017 & 2018





China HTA Mechanism (Drafted)

Table of contents

1. Organization of the HTA system.....	4	3.3 Project implementation and quality control	30
1.1 Organizational structure	4	3.3.1 Millstone management	30
1.1.1 National Center for Health Technology Assessment	5	3.3.2 Supervision and quality control	30
1.1.2 National HTA Expert Committee	54	Appraisal of evidence	31
1.1.3 National Health Technology Appraisal Committee	6	4.1 Appraisal committee and composition	31
1.1.4 National Collaborating Center for Health Technology Assessment	6	4.2 Procedures and approach	32
1.1.5 Health Technology Assessment Network	7	4.3 Principles and criteria	32
1.1.6 Third Party HTA agencies	8	4.4 Decisions on disputed findings	34
1.2 Key management mechanisms	10	Public consultation	34
1.2.1 Fundamental principles	10	5.1 Purpose	34
1.2.2 Process management	105	5.2 Consultees	34
1.2.3 Expert management	16	5.3 Process and timeline	35
(1) Expert recruitment and accountability	16	5.4 Processing feedbacks	35
1.3 Potential list of topics	18	Publications and translation	35
1.3.1 development of the potential list of topics	19	6.1 Publicizing results	35
1.3.2 Maintenance of the potential list of topics	20	6.2 Translation and implementation of results	36
1.3.3 Horizon scanning	20	6.2.1 Knowledge translation	36
2. Topic selection	226	6.2.2 Clinical pathways and quality standards	37
2.1 Priority setting	22	6.2.3 Essential care package	37
2.1.1 Regular topic selection	22	6.2.4 Pricing and payment policy	37
2.1.2 Emergency topic selection	26	6.2.5 Regulation of providers' behaviors	37
3. Commissioning of assessment projects	27		
3.1 Tendering and bidding management	28		
3.1.1 Responsible organization	28		
3.1.2 Process management	28		
3.2 Project commissioning	29		
3.2.1 Eligibility assessment of the project undertaker	29		
3.2.2 Contract signing	29		



China HTA Methods Guide (Drafted)

Table of Contents

Foreword	4
Acknowledgements	5
1 Introduction	6
1.1 The methods of technology appraisal	6
1.2 Health technologies and their selection	6
1.3 The components of health technology assessment	6
1.3.1 Topic selection / Scoping / Defining the decision problem	6
1.3.2 Assessment	7
1.3.3 Appraisal and decision-making	7
1.3.4 Fundamental principles	7
1.3.5 Implementation of HTA outcomes	8
2 Developing and defining the scope	9
2.1 Introduction	9
2.2 Components of the scope	9
2.2.1 Background information on the disease or health condition	9
2.2.2 The technology	9
2.2.3 The population	10
2.2.4 The comparator(s)	10
2.2.5 The evidence base	10
2.2.6 Health outcome measures	10
2.2.7 Costs	10
2.2.8 Other issues that may inform the appraisal	11
3 Evidence	12
3.1 Introduction	12
3.2 Guiding principles for evidence	12
3.3 Types of evidence	13
3.3.1 Randomised controlled trials	13
3.3.2 Non-randomised trials and single arm studies	13
4 Stakeholder involvement and participation	15
4.1 Manufacturers and sponsors	15
5 The reference case	16
5.1 Framework for estimating clinical and cost effectiveness	16
5.1.1 The concept of a reference case	16
5.1.2 Preferred type of economic evaluation	17
5.1.3 Transparency in the conduct of the economic evaluation (Principle 1)	20
5.1.4 Choice of comparator(s) (Principle 2)	20
5.1.5 Considering all available evidence (Principle 3)	20
5.1.6 Measuring and valuing health outcomes (Principle 4)	22
5.1.7 Differences between the intervention and the comparator in expected resource use and costs (Principle 5)	22
5.1.8 Time horizon and discounting (Principle 6)	22
5.1.9 Non-health effects and costs that do not accrue to the health budget (Principle 7) ..	23
5.1.10 Analysis of data for subpopulations (Principle 8)	23
5.1.11 Characterising uncertainty (Principle 9)	24
5.1.12 Impact on the China health sector and NHIB (Principle 10)	25
5.1.13 Equity considerations in cost-effectiveness analysis (Principle 11)	26
5.2 Modelling methods	27
5.3 Companion diagnostics (co-dependent technologies)	28
5.4 Presentation of data and results	28
6 Appraising the evidence and developing recommendations	30
6.1 Introduction	30
6.2 Appraisal of the evidence	30
6.3 Developing recommendations	33
6.4 Research recommendations	34
7 Further information	35
7.1 NAMMD HTA project team and Task Force	35
7.2 Bibliography	35
8 Glossary of terms	36



Capacity Building

- HTA Training Workshop (Feb. 2017 Xiamen, China)
- HTA Network Training Workshop (Jun. 2017 Guangzhou, China)
- Health Economics Modelling Training Workshop (Nov. 2017 Wuhan, China)
- 2nd HTA Network Annual Meeting (Nov. 2017 Wuhan, China)
- 1st HTA Training Workshop for Policy Makers & Researchers (May, 2018 Beijing, China)
- 2nd HTA Training Workshop for Policy Makers & Researchers (Jul, 2018 Shanghai, China)
- China HTA Conference (October, 2018 Beijing, China)





Dissemination

- The 3rd CEEC-China Health Minister Meeting
- HTA as a Topic in 2017 China-UK P2P High-Level Policy Dialogue
- WHO WPRO UHC TAG Meeting
- International HTA Meeting—HTAi, Asialink, ISPOR

Set platform of communication in HTA: CNHDRC and Shanghai HDRC share the HTA experience





国家卫生计生委卫生发展研究中心
China National Health Development Research Center

Beijing-- HTAi 2020 & 1st HTA Conference

HTAi Annual Meeting
Beijing, 2020

